Literature DB >> 19691925

What was wrong and might now go right with clinical trials for lupus?

Joan T Merrill1.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19691925     DOI： 10.1007/s11926-009-0044-y

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.592


× No keyword cloud information.
  3 in total

1.  Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes.

Authors:  T F Liu; B M Jones
Journal:  Cytokine       Date:  1998-02       Impact factor: 3.861

2.  Cytokine production, serum levels and disease activity in systemic lupus erythematosus.

Authors:  G Gröndal; I Gunnarsson; J Rönnelid; S Rogberg; L Klareskog; I Lundberg
Journal:  Clin Exp Rheumatol       Date:  2000 Sep-Oct       Impact factor: 4.473

Review 3.  B lymphocyte stimulator protein levels in systemic lupus erythematosus and other diseases.

Authors:  William Stohl
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592
  3 in total
  1 in total

1.  An update on belimumab for the treatment of lupus.

Authors:  Aikaterini Thanou-Stavraki; Amr H Sawalha
Journal:  Biologics       Date:  2011-02-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.